查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1471983

克罗恩病治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按药物类别、配销通路和地理位置

Crohn's Disease Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

克罗恩病治疗市场预计将从2023年的96.8亿美元成长到2031年的133.3亿美元；预计2023年至2031年复合年增长率为4.1%。

克罗恩病是一种主要影响胃肠道的慢性发炎疾病。它通常会影响小肠的末端和大肠的起始部分。此疾病的特征是消化道内壁炎症，导致腹痛、腹泻和营养不良等症状。克罗恩病治疗市场规模的不断增长归因于西方国家（尤其是美国）疾病盛行率的不断上升。此外，公司为保持竞争力而采取的策略性措施正在推动市场成长。医疗设备使用的显着增加可能会在预测期内带来新的克隆氏症治疗市场趋势。

精准医学在克隆氏症治疗中的渗透将为克隆氏症治疗市场的成长创造机会。

精准医学旨在根据每位患者的个别特征（包括环境因素、基因组成、生活方式和其他变数）调整药物治疗。在克隆氏症治疗中，精准医疗对于改善病患的治疗效果和最大程度地减少不良反应具有重要的保证。在克隆氏症治疗过程中，精准医学有多种应用方式，例如基因分析、生物标记、药物基因组学、标靶治疗以及预测建模和机器学习。在基因分析中，基因定序技术使研究人员能够发现与克隆氏症易感性和治疗反应相关的特定遗传变异。这将有助于他们选择可能反应良好的药物，并制定个人化的药物计划。

分析和检查与克罗恩病活动相关的特定生物标记将帮助研究人员更好地了解疾病的严重程度并预测更好的结果。标靶治疗是精准医学的另一种方法，它选择性地抑制导致克罗恩病发炎过程的特定分子。与传统疗法相比，这种个人化治疗提高了效率并降低了全身毒性。

精准医学进一步允许分层方法，根据既往疾病的特征、生物标记和各种遗传特征将患者分层到不同的亚群。此类治疗方法可以优化治疗反应率、最小化治疗反应率并改善克隆氏症治疗的长期结果。

预测建模和机器学习技术可以分析复杂的资料集，以识别模式并预测疾病进展。这允许整合遗传、临床和其他相关资料。预测建模技术可以支援临床医生做出明智的治疗决策并根据患者特征进行个人化治疗。

精准治疗透过允许采用不同遗传学、分子因素和临床因素的个人化治疗方法，在克隆氏症的治疗方面具有巨大的潜力。这种治疗在肠躁症中发挥重要作用，并优化了克隆氏症患者的治疗效果。

精准医学在治疗克隆氏症方面取得了显着进展，但许多目标仍未在基层实现。它需要庞大的资料、巨量资料、Hadoop等各种演算法工具以及先进的基础设施才能有效实施。在精准医学中实施先进的分析将为克罗恩病治疗市场创造巨大的机会。

根据地理位置，克隆氏症治疗市场分为北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙、俄罗斯和欧洲其他地区）、亚太地区（中国、日本、印度、韩国、澳洲、东南亚和亚太地区其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷、以及南美洲和中美洲其他地区）。由于生活方式因素，北美在 2023 年占据全球克隆氏症治疗市场的最大份额。然而，预计亚太地区 2023 年至 2031 年复合年增长率最高。 2022年，美国在北美克隆氏症治疗市场中占据最大份额。例如，2023年，美国食品药物管理局（FDA）批准了第一个口服药物－Rinvoq（upadacitinib）－用于治疗中重度克隆氏症。 Rinvoq 旨在治疗无法以阻断肿瘤坏死因子 (TNF) 的候选药物成功治疗的成年患者。此外，2021年，艾伯维公司宣布启动risankizumab治疗克隆氏症的3期试验。 Risankizumab 是一种人源化单株抗体，选择性靶向白血球介素 23 (IL-23) 路径。该试验旨在评估 risankizumab 对中度至重度克隆氏症患者的疗效和安全性。因此，上述因素支撑了市场的成长。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：克隆氏症治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：克隆氏症治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：克隆氏症治疗市场 - 全球市场分析

  • 克罗恩病治疗 - 全球市场概览
  • 克罗恩病治疗 - 全球市场和 2031 年预测

第 7 章：克隆氏症治疗市场 - 收入分析 - 按药物类别，2021-2031

  • 概述
  • 抗发炎药
  • 免疫系统抑制剂
  • 抗生素
  • 生物製剂
  • 止泻
  • 止痛药

第 8 章：克隆氏症治疗市场 - 收入分析 - 按配销通路，2021-2031

  • 概述
  • 医院药房
  • 零售药房
  • 网路药房

第 9 章：克隆氏症治疗市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
  • 南美洲和中美洲
    • 巴西
    • 阿根廷

第 10 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 12 章：克隆氏症治疗市场 - 主要公司概况

  • Abbvie, Inc.
  • Johnson and Johnson Private Limited
  • GlaxoSmithKline plc
  • Merck and CO., Inc.
  • Novartis AG.
  • Celgene Corporation
  • Genetech
  • Pfizer Inc.
  • Nestl
  • Boehringer Ingelheim GmbH

第 13 章：附录

简介目录
Product Code: TIPRE00004296

The Crohn's disease therapeutics market is expected to grow from US$ 9.68 billion in 2023 to US$ 13.33 billion by 2031; it is anticipated to record a CAGR of 4.1% from 2023 to 2031.

Crohn's disease is a chronic inflammatory condition primarily affecting the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive are fueling market growth. A significant increase in the use of medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.

Penetration of Precision Medicine for the Treatment of Crohn's disease will Create an Opportunity for Crohn's disease therapeutics market growth.

Precision medicine aims to modify the medical therapy to the individual characteristics of each patient, including environmental factors, genetic makeup, lifestyle, and other variables. In Crohn's disease therapy, precision medicine holds significant assurance for improving the patient's results and minimizing the adverse effects. There are a few ways precision medicine is applied during Crohn's disease therapy, like genetic profiling, biomarker identification, pharmacogenomics, targeted therapies, and predictive modeling & machine learning. In genetic profiling, genetic sequencing technologies allow the researcher to discover specific genetic variations associated with Crohn's disease susceptibility and treatment response. This will help them choose the medicine that is likely to respond well and allow for a personalized medication plan.

Analyzing and examining the specific biomarkers associated with Crohn's disease activity will help researchers better access disease severity and predict better outcomes. Targeted therapy is another method in precision medicine that selectively inhibits specific molecules responsible for the inflammatory process responsible for Crohn's disease. Such personalized treatment enhanced efficiency and reduced systemic toxicity compared with conventional therapies.

Precision medicine further allowed the stratification method, which allowed the stratification of patients into distinct subgroups based on the prior diseases' characteristics, biomarkers, and various genetic signatures. Such treatment approaches can optimize the treatment response rate, minimize the treatment response rate, and improve long-term outcomes in the treatment of Crohn's disease treatment.

Predictive modeling and machine learning techniques can analyze complex data sets to identify patterns and predict disease progression. This allows the integration of genetic, clinical, and other relevant data. Predictive modeling techniques can support the clinician in making informed treatment decisions and personalizing the therapy based on patient characteristics.

Precision therapy holds huge potential for the treatment of Crohn's disease therapy by allowing individualized treatment approaches with diverse genetics, molecular factors, and contributing clinical factors. This treatment plays a prominent role in irritable bowel syndrome and optimizes patient outcomes in managing Crohn's disease.

Precision medicine has significantly progressed in treating Crohn's diseases, but many objectives are still unmet on the ground level. It requires a huge data bank, various algorithm tools like big data, Hadoop, and advanced infrastructure with which it can be implemented effectively. Implementing advanced analytics in precision medicine will create huge opportunities for treating Crohn's disease therapeutics market.

Based on geography, the Crohn's disease therapeutics market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global Crohn's disease therapeutics market in 2023 owing to the lifestyle factor. However, Asia Pacific is predicted to register the highest CAGR during 2023-2031. The US held the largest share of the Crohn's disease therapeutics market in North America in 2022. Market players in the US are adopting organic and inorganic strategies for Crohn's disease therapeutics market development. For instance, in 2023, the US Food and Drug Administration (FDA) approved the first oral pill-Rinvoq (upadacitinib)-to treat moderate-to-severe Crohn's disease. Rinvoq is meant to treat adult patients who could not be treated successfully with drug candidates blocking tumor necrosis factor (TNF). Furthermore, in In 2021, AbbVie Inc. announced the initiation of the Phase 3 trial of risankizumab for the treatment of Crohn's disease. Risankizumab is a humanized monoclonal antibody that selectively targets the interleukin-23 (IL-23) pathway. The trial is aimed at evaluating the efficacy and safety of risankizumab in patients with moderate-to-severe Crohn's disease. Thus, the factors mentioned above support the market growth.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Crohn's Disease Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Crohn's Disease Therapeutics Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Crohn's Disease Therapeutics Market - Global Market Analysis

  • 6.1 Crohn's Disease Therapeutics - Global Market Overview
  • 6.2 Crohn's Disease Therapeutics - Global Market and Forecast to 2031

7. Crohn's Disease Therapeutics Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

  • 7.1 Overview
  • 7.2 Anti-inflammatory Drugs
  • 7.3 Immune System Suppressors
  • 7.4 Antibiotics
  • 7.5 Biologics
  • 7.6 Anti-diarrheal
  • 7.7 Pain Relievers

8. Crohn's Disease Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 8.1 Overview
  • 8.2 Hospital Pharmacy
  • 8.3 Retail Pharmacy
  • 8.4 Online Pharmacy

9. Crohn's Disease Therapeutics Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Crohn's Disease Therapeutics Market Overview
    • 9.1.2 North America Crohn's Disease Therapeutics Market Revenue and Forecasts to 2031
    • 9.1.3 North America Crohn's Disease Therapeutics Market Revenue and Forecasts and Analysis - By Drug Class
    • 9.1.4 North America Crohn's Disease Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 9.1.5 North America Crohn's Disease Therapeutics Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Crohn's Disease Therapeutics Market
        • 9.1.5.1.1 United States Crohn's Disease Therapeutics Market, by Drug Class
        • 9.1.5.1.2 United States Crohn's Disease Therapeutics Market, by Distribution Channel
      • 9.1.5.2 Canada Crohn's Disease Therapeutics Market
        • 9.1.5.2.1 Canada Crohn's Disease Therapeutics Market, by Drug Class
        • 9.1.5.2.2 Canada Crohn's Disease Therapeutics Market, by Distribution Channel
      • 9.1.5.3 Mexico Crohn's Disease Therapeutics Market
        • 9.1.5.3.1 Mexico Crohn's Disease Therapeutics Market, by Drug Class
        • 9.1.5.3.2 Mexico Crohn's Disease Therapeutics Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Crohn's Disease Therapeutics Market - Key Company Profiles

  • 12.1 Abbvie, Inc.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 12.2 Johnson and Johnson Private Limited
  • 12.3 GlaxoSmithKline plc
  • 12.4 Merck and CO., Inc.
  • 12.5 Novartis AG.
  • 12.6 Celgene Corporation
  • 12.7 Genetech
  • 12.8 Pfizer Inc.
  • 12.9 Nestl
  • 12.10 Boehringer Ingelheim GmbH

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud